Oric Pharmaceuticals, Inc. (ORIC)
7.36
-0.34
(-4.42%)
USD |
NASDAQ |
Nov 20, 16:00
7.35
-0.01
(-0.14%)
After-Hours: 20:00
Oric Pharmaceuticals Debt to Equity Ratio : 0.0099 for Sept. 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2026 | 0.0099 |
| June 30, 2026 | 0.0087 |
| March 31, 2026 | 0.0079 |
| December 31, 2025 | 0.0194 |
| September 30, 2025 | 0.0081 |
| June 30, 2025 | 0.0101 |
| March 31, 2025 | 0.0146 |
| December 31, 2024 | 0.0385 |
| September 30, 2024 | 0.0114 |
| June 30, 2024 | 0.0092 |
| March 31, 2024 | 0.0084 |
| December 31, 2023 | 0.0456 |
| September 30, 2023 | 0.011 |
| June 30, 2023 | 0.0101 |
| Date | Value |
|---|---|
| March 31, 2023 | 0.0132 |
| December 31, 2022 | 0.0544 |
| September 30, 2022 | 0.0123 |
| June 30, 2022 | 0.011 |
| March 31, 2022 | 0.008 |
| December 31, 2021 | 0.0456 |
| September 30, 2021 | 0.0062 |
| June 30, 2021 | 0.0062 |
| March 31, 2021 | 0.0067 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
| December 31, 2019 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.0518 |
| Alnylam Pharmaceuticals, Inc. | 0.8316 |
| Anika Therapeutics, Inc. | 0.1901 |
| Savara, Inc. | 0.2815 |
| Arrowhead Pharmaceuticals, Inc. | 27.84 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 366.89M |
| Total Liabilities (Quarterly) | 27.38M |
| Shareholders Equity (Quarterly) | 339.50M |
| Current Ratio | 11.09 |
| Net Debt Paydown Yield | 0.00% |